SME Times is powered by   
Search News
Just in:   • Adani Group to invest Rs 57,575 crore in Odisha  • 'Dollar Distancing' finally happening? Time for India to pitch Rupee as credible alternative: SBI Ecowrap  • 49% Indian startups now from tier 2, 3 cities: Jitendra Singh  • 'India ranks 3rd in global startup ecosystem & number of unicorns'  • LinkedIn lays off entire global events marketing team: Report 
Last updated: 27 Sep, 2014  

CROMSOURCE Upgrades to the new Oracle Clinical Release 4.6.4

PR Newswire | 29 Jan, 2013
CROMSOURCE Upgrades to the new Oracle Clinical Release 4.6.4

VERONA, Italy: CROMSOURCE, a high quality ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions, today announced successful completion of a project to upgrade their data management system to the new Oracle Clinical Release 4.6.4 (replacing version 4.5.3.).

'Over the past 15 years, the Biometrics group within CROMSOURCE has conducted hundreds of important projects either as part of full-service agreements or as stand-alone assignments across all segments of the healthcare research sector, including medical devices, pharmaceuticals, biotechnologies and vaccines,' noted Hugo Hartmans, Director of Biometrics. 'We consistently delight our clients by delivering high quality services and proactively searching for the most efficient solution. As part of this commitment to satisfy our clients' needs, evidenced by our 80% repeat business level, CROMSOURCE decided to invest in upgrading to the latest Oracle Clinical Release.'

Key benefits of the upgrade include availability of web-based randomisation, provision of email alerts on entry of certain defined data (e.g. SAEs), increased flexibility of eCRF design and flow, conditional navigation and other increases in general usability. The combined effect of these changes is to increase the ease, speed and accuracy of data handling which in turn creates cleaner data, faster.

The upgraded version of Oracle Clinical and Remote Data Capture (RDC) is now installed and hosted on the state-of-the-art infrastructure in the CROMSOURCE European Headquarters, and is fully validated and maintained in accordance with all applicable international guidelines.

'This is an important milestone and reflects our commitment to remaining at the forefront of technological innovation and providing best in class solutions to our clients,' stated Oriana Zerbini MD, Chief Executive Officer of CROMSOURCE. 'CROMSOURCE has an enviable record of delivering high quality statistics and data management projects to our sponsors on time, on budget and to the highest quality. I am convinced that this development will create many added benefits for our clients.'

About CROMSOURCE: CROMSOURCE is a high quality ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions. The CROMSOURCE Biometrics team is headquartered in Aachen, Germany, with another large group working from the CROMSOURCE office in Stirling in the UK. During the last 15 years the Biometrics group at CROMSOURCE has completed over 230 data management projects and over 50 EDC based studies.

Contact: Margherita Mosconi
CROMSOURCE
Phone: +39-045-8222811
Fax: +39-045-8222812

(European Headquarters)
Via Scuderlando, 10
37135 Verona, Italy
http://www.cromsource.com

 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
66.20
64.50
UK Pound
87.50
84.65
Euro
78.25
75.65
Japanese Yen 58.85 56.85
As on 13 Aug, 2022
  Daily Poll
PM Modi's recent US visit to redefine India-US bilateral relations
 Yes
 No
 Can't say
  Commented Stories
» GIC Re's revenue from obligatory cession threatened(1)
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter